Programmed death 1 blockade, an Achilles heel for MMR-deficient tumors?

Journal of Hematology and Oncology

Volumn 8, Issue 1, 2015, Pages

  Lin, Andy Yingjie ^a   Lin, Edward ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; MLH1 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; MUTL PROTEIN HOMOLOG 1; NUCLEAR PROTEIN; PDCD1 PROTEIN, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COLON CANCER; COLORECTAL CANCER; CPG ISLAND; DRUG TARGETING; EPIGENETICS; GENE MUTATION; GENETIC DAMAGE; HUMAN; METASTASIS; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; NEOPLASM; OVERALL SURVIVAL; PD 1 GENE; PHENOTYPE; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; RECEPTOR BLOCKING; REVIEW; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; COLORECTAL NEOPLASMS; DEFICIENCY; GENETICS; METABOLISM; MUTATION; NEOPLASMS; SURVIVAL ANALYSIS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DNA MISMATCH REPAIR; HUMANS; MUTATION; MUTL PROTEIN HOMOLOG 1; NEOPLASMS; NUCLEAR PROTEINS; PROGRAMMED CELL DEATH 1 RECEPTOR; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84960105388     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/s13045-015-0222-5     Document Type: Review

References (31)

1. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015:33(17);1974-1982.
2. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012:366(26);2455-2465.
3. Shi L, Chen S, Yang L. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol. 2013;6:74.
4. Rizvi NA, Hellmann MD, Snyder A, Kvistborg P, Makarov V, Havel JJ, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science 2015:348(6230);124-128.
5. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014:371(23);2189-2199.
6. Imai K, Yamamoto H. Carcinogenesis and microsatellite instability: The interrelationship between genetics and epigenetics. Carcinogenesis. 2008;29:673-80.
7. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 2003;21(6):1174-1179.
8. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015:372(26);2509-2520.
9. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science 2015;348(6230):69-74.
10. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000:342(2);69-77.
11. Ruemmele P, Dietmaier W, Terracciano L, Tornillo L, Bataille F, Kaiser A, et al. Histopathologic features and microsatellite instability of cancers of the papilla of vater and their precursor lesions. Am J Surg Pathol 2009:33(5);691-704.
12. Liu W, Shia J, Gonen M, Lowery MA, O'Reilly EM, Klimstra DS. DNA mismatch repair abnormalities in acinar cell carcinoma of the pancreas: Frequency and clinical significance. Pancreas 2014:43(8);1264-1270.
13. Jensen KC, Mariappan MR, Putcha GV, Husain A, Chun N, Ford JM, et al. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. Am J Surg Pathol 2008:32(7);1029-1037.
14. Xiao X, Melton DW, Gourley C. Mismatch repair deficiency in ovarian cancer-molecular characteristics and clinical implications. Gynecol Oncol 2014;132(2):506-512.
15. Jonsson M, Johannsson O, Borg A. Infrequent occurrence of microsatellite instability in sporadic and familial breast cancer. Eur J Cancer 1995;31A(13-14):2330-2334.
16. Sinicrope FA. DNA mismatch repair and adjuvant chemotherapy in sporadic colon cancer. Nat Rev Clin Oncol 2010;7(3):174-177.
17. Brueckl WM, Heinze E, Milsmann C, Wein A, Koebnick C, Jung A, et al. Prognostic significance of microsatellite instability in curatively resected adenocarcinoma of the small intestine. Cancer Lett 2004:203(2);181-190.
18. Prtilo A, Leach FS, Markwalder R, Kappeler A, Burkhard FC, Cecchini MG, et al. Tissue microarray analysis of hMSH2 expression predicts outcome in men with prostate cancer. J Urol 2005:174(5);1814-1818; discussion 1818.
19. Resnick KE, Frankel WL, Morrison CD, Fowler JM, Copeland LJ, Stephens J, et al. Mismatch repair status and outcomes after adjuvant therapy in patients with surgically staged endometrial cancer. Gynecol Oncol 2010:117(2);234-238.
20. Cohn DE, Frankel WL, Resnick KE, Zanagnolo VL, Copeland LJ, Hampel H, et al. Improved survival with an intact DNA mismatch repair system in endometrial cancer. Obstet Gynecol 2006:108(5);1208-1215.
21. Garg K, Leitao MM, Jr., Kauff ND, Hansen J, Kosarin K, Shia J, et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol 2009:33(6);925-933.
22. De Smedt L, Lemahieu J, Palmans S, Govaere O, Tousseyn T, Van Cutsem E, et al. Microsatellite instable vs stable colon carcinomas: Analysis of tumour heterogeneity, inflammation and angiogenesis. Br J Cancer 2015.
23. Meyers M, Wagner MW, Hwang HS, Kinsella TJ, Boothman DA. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res 2001:61(13);5193-5201.
24. Fink D, Zheng H, Nebel S, Norris PS, Aebi S, Lin TP, et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res 1997:57(10);1841-1845.
25. Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998;4(1):1-6.
26. Han EQ, Li XL, Wang CR, Li TF, Han SY. Chimeric antigen receptor-engineered T cells for cancer immunotherapy: Progress and challenges. J Hematol Oncol 2013:6;47.
27. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001:344(16);1196-1206.
28. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002:418(6901);934.
29. Huang T, Karsy M, Zhuge J, Zhong M, Liu D. B-Raf and the inhibitors: From bench to bedside. J Hematol Oncol 2013:6;30.
30. Akinleye A, Furqan M, Mukhi N, Ravella P, Liu D. MEK and the inhibitors: From bench to bedside. J Hematol Oncol 2013:6;27.
31. Smith AD, Roda D, Yap TA. Strategies for modern biomarker and drug development in oncology. J Hematol Oncol. 2014;7(1):70.